Patents
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
02/2004
02/19/2004US20040033983 Dietetic mixtures comprising polyglucomannans, excipients and lipase inhibitors such as orlistat
02/19/2004US20040033982 Viral inhibition by n-docosanol
02/19/2004US20040033968 Comprises fungicides and moisturizers; side effect reduction
02/19/2004US20040033960 Ophthalmic irrigating solution adapted for use in lasik surgery
02/19/2004US20040033959 Improved bioavailability
02/19/2004US20040033955 Treatment of ophthalmic infections using antimicrobial peptides
02/19/2004US20040033949 Use of VEGF for treating bone defects
02/19/2004US20040033938 Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
02/19/2004US20040033933 Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof
02/19/2004US20040033487 Comprises nucleotide sequences coding associated with glycosylation of viral structural polypeptides; prototype immunogens for treatment and prevention of viral disease; genetic vaccines
02/19/2004US20040033275 Extracted with ethanol/water mixed with a heavy metal chelator; primary extract is concentrated with Indian Sterculia gum or one or more polymers such as a polysaccharides
02/19/2004US20040033267 Nanoparticulate compositions of angiogenesis inhibitors
02/19/2004US20040033266 Pharmaceutically active particles of a monomodal particle size distribution and method
02/19/2004US20040033265 Composite matrix containing chitosan derivatives and a process for making the same
02/19/2004US20040033264 Composite hydrogel drug delivery systems
02/19/2004US20040033263 Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation
02/19/2004US20040033262 Sustained release pharmaceutical composition of a cephalosporin antibiotic
02/19/2004US20040033261 Gellan gum tablet film coating
02/19/2004US20040033259 Particularly levothyroxine sodium; unit dosage form containing an alditol, a saccharide, and optionally further excipients
02/19/2004US20040033258 Compression molded blend of a basic medicinal component having an unpleasant taste, a saccharide, a polyanionic polymer, a corrigent, and carboxymethylcellulose; quickly disintegrating in the oral cavity.
02/19/2004US20040033257 Pharmaceutical formulation in a drug delivery system and process for preparing the same
02/19/2004US20040033256 Long-acting insulin formulation that may be aerosolized for pulmonary administration.
02/19/2004US20040033255 For preventing, inhibiting, and/or diminishing the intentional and/ or inadvertent misuse or abuse of a transdermal delivery device
02/19/2004US20040033254 Transdermal drug delivery system with improved water absorbability and adhesion properties
02/19/2004US20040033253 Transdermal-delivery device
02/19/2004US20040033250 Implantable polymeric device for sustained release of buprenorphine
02/19/2004US20040033245 Pharmaceutical suspensions, compositions and methods
02/19/2004US20040033242 Two dimensional polymer that generates nitric oxide
02/19/2004US20040033241 The botulinum toxin is released from the carrier upon implantation in a human patient.
02/19/2004US20040033233 Dried powder form in sachet or in capsule of root, bark and wood of Philippine Narra tree (Pterocarpus Indicus)
02/19/2004US20040033228 High protein concentration, a pH of between about 4 and about 8, and enhanced stability; tumor necrosis factor alpha (tnf-alpha)
02/19/2004US20040033220 Use of enzymes obtained from ciliates as medicaments for promoting digestion
02/19/2004US20040033202 Nanoparticulate sterol formulations and novel sterol combinations
02/19/2004US20040033201 Aerosol container has a non-metal interior surface which has been found to reduce chemical degradation of such steroids
02/19/2004US20040032187 Devices for intrabody delivery of molecules and systems and methods utilizing same
02/19/2004US20040032037 Equipped with line for transporting polar liquid phase, line for transporting organic liquid phase containing lipids, collecting receptacle for accommodating product lipid vesicles, means for conveying produced vesicles through lines
02/19/2004US20040031447 Animal papilla disinfectants and method of improving microbial environment
02/19/2004DE19930030B4 CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform CO-3 unsaturated fatty acids containing oral dosage form
02/19/2004DE19860373B4 Mundpflegemittel und Verwendung von sphärischen Mikropartikeln The oral care composition and use of spherical microparticles
02/19/2004DE10248412A1 Rapidly acting, easily administered suppositories for treatment and/or prophylaxis of hypoglycemia, preferably comprising monosaccharide (source) as active agent
02/19/2004DE10236319A1 Active agent containing matrix plaster for the controlled delivery of an active agent to the skin comprises a pharmaceutical active agent containing a water insoluble adhesive matrix comprising a styrene block copolymer
02/19/2004DE10235475A1 Composition in the form of pellets containing benzimidazole useful for treating gastric disorders comprises an inert core to which a layer containing benzimidazole with microcrystalline cellulose is applied and outer layer
02/19/2004DE10234784A1 Intravenös applizierbare, pharmazeutische Darreichungsform Administered Intravenously, pharmaceutical dosage form
02/19/2004DE10234673A1 Heißschmelz-TTS zur Verabreichung von Rotigotin Hot melt TTS for the administration of rotigotine
02/19/2004DE10217555A1 Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix Physiologically acceptable, phospholipid-containing, stable and hard matrix
02/19/2004DE10214031A1 Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation Process for the preparation and application of micro- and nanoparticles by constructive micronization
02/19/2004CA2809147A1 Compositions and process for delivering an additive
02/19/2004CA2497452A1 Compositions and process for delivering an additive
02/19/2004CA2495172A1 Active agent delivery systems, medical devices, and methods
02/19/2004CA2495103A1 Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
02/19/2004CA2495071A1 Isosorbide mononitrate compositions and methods of their use
02/19/2004CA2494911A1 Immunomodulatory compositions, methods of making, and methods of use thereof
02/19/2004CA2494865A1 Electrospun amorphous pharmaceutical compositions
02/19/2004CA2494716A1 Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
02/19/2004CA2494699A1 Palatable controlled-release formulation for companion animals
02/19/2004CA2494186A1 Active agent delivery system including a poly(ethylene-co-(meth)acrylate), medical device, and method
02/19/2004CA2494065A1 Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine
02/19/2004CA2493120A1 Implantable artifical pancreas
02/19/2004CA2491136A1 A chemical carrier
02/18/2004EP1389469A1 Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
02/18/2004EP1389468A1 Compositions for promoting healing of bone fracture
02/18/2004EP1389467A1 Therapeutic compositions for repairing chondropathy
02/18/2004EP1389466A1 Immunopotentiators
02/18/2004EP1389462A1 Amorphous cefditoren pivoxil composition and process for producing the same
02/18/2004EP1389212A1 3,7-diazabicyclo 3.3.1] formulations as anti-arrythmic compounds
02/18/2004EP1389211A1 3,7-diazybicyclo 3.3.1] formulations as antiarrhytmic compounds
02/18/2004EP1389137A2 Compositions for protein delivery via the pulmonary route
02/18/2004EP1389124A1 Palliative effects of morinda citrifolia oil and juice
02/18/2004EP1389118A1 Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
02/18/2004EP1389115A2 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
02/18/2004EP1389109A1 Gastric acid secretion inhibiting composition
02/18/2004EP1389108A2 Methods for selective immunomodulation using pimecrolimus
02/18/2004EP1389106A1 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
02/18/2004EP1389099A1 Delivery of beta-blockers through an inhalation route
02/18/2004EP1389098A1 Delivery of antipsychotics through an inhalation route
02/18/2004EP1389097A1 Delivery of compounds for the treatment of parkinsons through an inhalation route
02/18/2004EP1389096A1 Delivery of opioids through an inhalation route
02/18/2004EP1389095A1 Delivery of antidepressants through an inhalation route
02/18/2004EP1389094A1 Delivery of sedative-hypnotics trough an inhalation route
02/18/2004EP1389093A2 Pharmaceutical formulation
02/18/2004EP1389092A1 Abuse-resistant opioid dosage form
02/18/2004EP1389091A1 Granular preparations of gaboxadol
02/18/2004EP1389089A2 Method and composition for solubilising a biologically active compound with low water solubility
02/18/2004EP1389086A1 Topical compositions containing nonimmunosuppressive cyclosporin-derivatives for treating hair loss
02/18/2004EP1267932B1 Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails
02/18/2004EP1240261B1 Medicament delivery device with moisture resistant coating
02/18/2004EP1237408B1 Pour-on formulations
02/18/2004EP1194136B1 Non-solid composition for local application comprising glycerol and alchemilla vulgaris extract
02/18/2004EP1187635B1 Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist
02/18/2004EP1137407B1 Ophthalmic formulation comprising a beta blocker and carbopol
02/18/2004EP1131089B1 Stable aqueous insulin preparations without phenol and cresol
02/18/2004EP1082293B1 Formoterol polymorphs
02/18/2004EP1032396B1 Sterilization of glucocorticosteroids
02/18/2004EP0994696B1 Controlled release pharmaceutical preparation with ace inhibitor as active agent
02/18/2004EP0967995B1 Composition comprising immunoglobulin
02/18/2004EP0863765B1 Pharmaceutical compositions of cyclosporine with a polyethoxylated saturated hydroxy-fatty acid
02/18/2004CN1476335A Freeze-dried pantoprazole preparation and pantoprazole injection
02/18/2004CN1476330A Polymeric micelle containing cisplatin enclosed therein and use thereof
02/18/2004CN1476327A Water-soluble liquid internal medicine
02/18/2004CN1476325A Active agent delivery systems and methods for protecting and administering active agents